PMHNP Scope of Practice for Narcolepsy in Pennsylvania

If you’re a psychiatrist or PMHNP considering treating narcolepsy patients through telehealth, you’re entering a regulatory minefield — but also a massive opportunity. Narcolepsy is underdiagnosed, specialists are scarce, and patients desperately need access to care. The problem? The medications that actually work — stimulants like Adderall, modafinil, sodium oxybate — are controlled substances wrapped in layers of federal and state red tape.

Here’s the reality: as of early 2026, you can prescribe these medications via telehealth in most states, thanks to temporary DEA flexibilities. But those flexibilities are just that — temporary. The rules are changing, state laws vary wildly, and if you’re an NP, your ability to prescribe depends entirely on where you’re licensed.

This guide cuts through the confusion. We’ll walk through the current federal telehealth waivers, what happens when they expire, how each state treats NP prescribing authority for Schedule II stimulants, and what you need to operationalize narcolepsy care remotely without running afoul of the law.

The Federal Landscape: DEA Telehealth Flexibilities (And When They End)

Let’s start with the baseline: the Ryan Haight Act. Passed in 2008, this federal law requires an in-person medical evaluation before prescribing any controlled substance via the internet or telemedicine. That meant pre-COVID, you couldn’t legally start a patient on Adderall or modafinil via video — you had to see them face-to-face at least once.

Then March 2020 hit. The DEA waived the in-person requirement for the duration of the COVID-19 Public Health Emergency, allowing providers to prescribe Schedule II–V medications via telehealth (video or phone) without ever meeting the patient in person, as long as the prescription was legitimate and all other rules (state licensure, DEA registration, standard of care) were followed.

The emergency ended in May 2023, but the DEA kept extending the telehealth flexibilities — first through late 2023, then through 2024, and most recently through December 31, 2026 (HHS Press Release, Jan 2, 2026). Why? Because they still haven’t finalized permanent telemedicine prescribing rules. Over 38,000 public comments came in on their 2023 proposed rules (which would have severely restricted telehealth prescribing of stimulants), and DEA went back to the drawing board (DEA Announcement, Nov 15, 2024).

What this means for you right now:
Through the end of 2026, you can evaluate a narcolepsy patient via video, diagnose them, and prescribe stimulants (methylphenidate, amphetamines), modafinil, or sodium oxybate without an in-person visit — as long as you’re DEA-registered, licensed in the patient’s state, and practicing within the standard of care.

What happens after 2026?
Nobody knows for sure. The DEA will eventually finalize rules. They might require an initial in-person exam, or allow telehealth with a 30-day supply limit until follow-up, or carve out exceptions for established diagnoses like narcolepsy (similar to what they did for buprenorphine in opioid use disorder). The only certainty is that purely audio-only prescribing will likely end, and documentation standards will tighten.

Practical takeaway: If you’re building a telehealth narcolepsy practice, plan for a hybrid model. Partner with local sleep centers or primary care clinics where patients can get the required polysomnogram and MSLT (which you need for diagnosis anyway), and potentially an in-person physical exam to satisfy future DEA requirements. Don’t build your entire practice assuming the current waivers are permanent.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Reality Check: Where You Can (and Can’t) Prescribe Stimulants for Narcolepsy via Telehealth

Federal law sets the floor, but state laws control who can prescribe what, how, and to whom. Some states align with federal flexibilities. Others impose their own restrictions that hit narcolepsy hard.

Florida: The Telehealth Trap

Florida is the outlier you need to watch. Florida Statute 456.47 explicitly prohibits prescribing Schedule II or III controlled substances via telehealth except in four narrow scenarios: treating a psychiatric disorder, inpatient hospital care, hospice, or nursing home residents (Fla. Stat. §456.47).

Narcolepsy is not a psychiatric disorder — it’s a neurological sleep disorder. That means:

• You cannot prescribe Adderall, Ritalin, or other Schedule II stimulants for narcolepsy via telehealth alone in Florida. You need at least one in-person visit.
• You can prescribe modafinil or armodafinil (Schedule IV) via telehealth, since the ban only covers Schedule II and III.
• If you’re a PMHNP in Florida, you face an additional hurdle: Florida limits NPs to a 7-day supply of Schedule II medications unless you’re a designated ‘psychiatric nurse’ prescribing for a mental health disorder (Fla. Stat. §464.012). Since narcolepsy isn’t mental health, that 7-day cap applies even if you arrange an in-person exam.

Bottom line for Florida: If you’re treating narcolepsy patients there, plan on modafinil as your first-line telehealth option, or coordinate with a local physician who can write the stimulant prescriptions after an in-person visit.

Texas: NPs Can’t Touch Schedule II Outpatient

Texas allows telehealth prescribing for physicians — no problem there. But if you’re a PMHNP, you hit a wall.

Texas law prohibits APRNs and PAs from prescribing Schedule II controlled substances in outpatient settings. The only exceptions are inpatient hospital admissions (≥24 hours), emergency departments, or hospice care — and even then, the prescription must be filled at the facility pharmacy (Texas Medical Board FAQ).

What does this mean?
A Texas PMHNP cannot prescribe Adderall or methylphenidate for a narcolepsy patient in your telehealth clinic. Period. Your supervising physician has to write those prescriptions.

You can prescribe modafinil (Schedule IV) under delegation, assuming your collaborative agreement allows it. But if your narcolepsy patients need stimulants — and many do — you’ll need an MD or DO on your team.

California, New York, Illinois: NP-Friendly (If You Meet Requirements)

These three states have moved toward full practice authority for experienced NPs, which includes prescribing Schedule II medications independently.

California (AB 890):
As of 2023, NPs with ≥4,600 hours of practice experience can practice independently, including prescribing Schedule II–V controlled substances (RxAgent NP Authority Guide). You need to complete specified pharmacology training on controlled substances and obtain a DEA registration, but once you do, you can manage narcolepsy patients end-to-end — diagnosis, sleep study coordination, stimulant prescriptions, follow-up.

New York:
Experienced NPs (≥3,600 hours) have had independent practice authority since 2022 (Rivkin Radler Law Blog, April 2022). New York’s 2025 controlled substance telehealth rule requires an in-person exam unless you’re complying with federal law — which currently allows telehealth under the DEA waiver (Nixon Peabody Alert, June 2025). So right now, you’re good. When the DEA waiver expires, you’ll need to follow whatever the new federal rules require or use one of NY’s exceptions (e.g., patient was recently seen in person by a referring provider).

Illinois:
Illinois NPs can attain full practice authority after 4,000 hours of collaboration + 250 hours of continuing education. Once you have FPA, you can prescribe Schedule II–V independently (you’ll need a state mid-level controlled substance license on top of your DEA registration). Illinois law requires a ‘consultation relationship’ with a physician if you prescribe benzodiazepines or opioids, but stimulants aren’t covered by that rule — so you can prescribe Adderall for narcolepsy solo.

Pennsylvania: Physician Collaboration Required, 30-Day Limit on Schedule II

Pennsylvania is a restricted practice state. CRNPs must have a collaborative agreement with a physician and cannot prescribe more than a 30-day supply of Schedule II medications without physician consultation (PA Bulletin, 2021-2022).

For narcolepsy care, this means:

• You can initiate stimulant therapy via telehealth (under the DEA waiver), but after 30 days, your collaborating physician needs to review the patient and approve continuation.
• Your collaborative agreement must explicitly delegate Schedule II prescribing authority to you.
• You must use video for the telehealth evaluation (audio-only isn’t sufficient for controlled substances in PA).

It’s workable, but it requires tight coordination with your supervising physician.

The Diagnostic Challenge: You Still Need a Sleep Study

Here’s the non-negotiable reality of narcolepsy: you can’t diagnose it purely on history alone. The gold standard requires:

1. Overnight polysomnography (to rule out sleep apnea and other causes)
2. Multiple Sleep Latency Test (MSLT) the next day (to document pathological sleepiness and REM latency)

These tests are in-person, conducted in a sleep lab or home sleep testing setup. Some states explicitly require objective testing before prescribing stimulants long-term for narcolepsy (it’s part of the standard of care, even if not legally mandated).

How to handle this in telehealth:

• Build referral relationships with sleep centers in the states where you practice. Order the tests remotely, review the results, confirm the diagnosis.
• For established patients transferring to your care who already have a confirmed diagnosis (with documented sleep study results), you can continue their medications via telehealth.
• Document everything. If you’re relying on an outside sleep study, get the actual report — not just a diagnosis code — and include it in your chart. DEA and state medical boards will look for this if you’re audited.

Some providers are experimenting with home sleep apnea tests (HSAT) for the polysomnography portion, which can be mailed to patients. However, the MSLT still requires an in-person lab visit (you need EEG and trained techs to score sleep onset and REM latency). There’s no way around this yet.

Special Considerations: Sodium Oxybate (Xyrem) and REMS Programs

If you’re treating narcolepsy with cataplexy, your patients may need sodium oxybate (Xyrem, Xywav) — a Schedule III medication with one of the strictest distribution systems in the U.S.

Sodium oxybate is only available through the Xyrem/Xywav REMS program. You must:

• Enroll as a prescriber in the REMS database
• Certify patients and pharmacies
• Use the manufacturer’s central pharmacy for dispensing (patients can’t fill it at CVS)

This adds administrative overhead, but it’s doable via telehealth. The evaluation and prescription can be done remotely; the pharmacy ships directly to the patient.

Important: Sodium oxybate prescriptions are subject to the same telehealth rules as other controlled substances. You still need to comply with DEA waivers (or eventual permanent rules) and state law.

Economics: Why Telehealth Platforms Make Sense for Narcolepsy Providers

Let’s talk money. If you’re thinking about marketing yourself to narcolepsy patients independently — SEO, Google Ads, Psychology Today listings — here’s the cold reality:

Traditional marketing for psychiatric patients is expensive and slow:

• SEO: 6-12 months before you see meaningful traffic. You’re competing with established sleep clinics and neurologists who’ve been at it for years.
• Google Ads: Mental health keywords cost $15-40+ per click. Most clicks don’t convert to booked appointments. A realistic cost per booked patient is $200-400+.
• Directories (Psychology Today, Zocdoc): Monthly subscription fees, plus you’re one of hundreds of providers on the same page. Zocdoc charges $35-100+ per booking, and that doesn’t include the monthly subscription. Total monthly cost easily hits $500-1,000 with uncertain ROI.

When you add it all up — agency fees, ad spend testing, staff time to handle and qualify leads, no-show rates from cold leads — acquiring a qualified psychiatric patient through DIY marketing typically costs $200-500+ per patient, and that’s assuming your campaigns work. Many don’t.

The platform model flips the economics:
Platforms like Klarity Health use a pay-per-appointment model. You pay a standard listing fee per new patient lead — only when a qualified patient actually books with you. No upfront marketing spend, no monthly subscription fees, no wasted ad spend on clicks that don’t convert.

Here’s why that matters for narcolepsy specifically:

• Narcolepsy patients are actively seeking specialists. They’ve often been bounced between primary care, neurologists, and sleep clinics. They’re searching for providers who understand the condition and can prescribe what they need.
• The platform pre-qualifies patients and matches them to your specialty and availability. You’re not paying for tire-kickers or no-shows.
• You get both insurance and cash-pay patient flow, without building separate billing infrastructure.
• The built-in telehealth platform handles video visits, e-prescribing integration, and compliance documentation.

Instead of spending $3,000-5,000/month on marketing with uncertain results, you pay only when you see patients. That’s guaranteed ROI vs. gambling on marketing channels you may not have the expertise or patience to optimize.

Can DIY marketing eventually be cost-effective? Sure — if you have the budget, the expertise, and 12-18 months to wait for SEO to kick in. But for most providers, especially those starting out or scaling quickly, the platform model removes the risk entirely.

Compliance Checklist: How to Avoid Regulatory Landmines

If you’re going to treat narcolepsy via telehealth, here’s your compliance baseline:

Federal (DEA):

• [ ] Hold an active DEA registration with Schedule II authority
• [ ] Licensed in the state where the patient is physically located
• [ ] Documented video (or audio-visual) evaluation meeting standard of care
• [ ] Prescription is for a legitimate medical purpose within usual course of practice
• [ ] E-prescribing of controlled substances (EPCS) with two-factor authentication

State-Specific (check your state):

• [ ] PDMP query before each controlled substance prescription (required in nearly all states)
• [ ] State-specific telehealth consent (some states require signed acknowledgment)
• [ ] Collaborating physician agreement (if you’re an NP in TX, FL, PA, etc.)
• [ ] State controlled substance registration or reporting (NY requires I-STOP registration; IL requires mid-level CS license)
• [ ] Video requirement (Texas and some others mandate two-way video for controlled meds)

Clinical Documentation:

• [ ] Sleep study results (polysomnography + MSLT) confirming narcolepsy diagnosis
• [ ] Epworth Sleepiness Scale or similar validated tool
• [ ] Documentation of why controlled medication is necessary (e.g., tried modafinil, insufficient response)
• [ ] Informed consent specific to controlled substances (abuse potential, side effects, monitoring plan)
• [ ] Treatment agreement for long-term stimulant therapy (optional but recommended)

Risk Management:

• [ ] Malpractice insurance covers telehealth and controlled substance prescribing
• [ ] Regular follow-ups (monthly initially, then quarterly once stable) to monitor efficacy and side effects
• [ ] Emergency plan documented in chart (what patient should do if severe side effects or medication stolen)

What’s Coming: Preparing for Post-2026 DEA Rules

The current telehealth flexibilities end December 31, 2026. What should you be planning for?

Most likely scenarios:

1. Initial 30-day limit: DEA allows telehealth prescribing of Schedule II stimulants for an initial 30-day supply, then requires an in-person visit or video re-evaluation with tighter documentation.
2. Diagnosis-specific exceptions: DEA creates carve-outs for established diagnoses (like narcolepsy or ADHD) where ongoing telehealth prescribing is allowed after initial verification.
3. Special registration pathway: DEA implements a ‘telemedicine special registration’ allowing qualified providers to prescribe controlled substances nationwide via telehealth (this was proposed but not yet implemented).

What you should do now:

• Build hybrid workflows: Partner with local clinics or sleep centers in the states where you practice so you have an in-person option if needed.
• Document meticulously: When the rules tighten, auditors will look for evidence of thorough evaluation, ongoing monitoring, and clinical justification for remote prescribing.
• Diversify your patient base: Don’t rely 100% on stimulant-dependent narcolepsy patients. Modafinil (Schedule IV) will almost certainly remain prescribable via telehealth, and some patients respond well to it.
• Stay informed: Join professional organizations (AASM, APA, AANP) that track DEA rulemaking. Comment on proposed rules when the DEA publishes them — provider input matters.

Why Psychiatrists and PMHNPs Are Uniquely Positioned for Telehealth Narcolepsy Care

Neurologists and sleep specialists are overwhelmed. Wait times for sleep clinic appointments in many states exceed 3-6 months. Primary care providers often aren’t comfortable managing narcolepsy long-term (especially cataplexy or complex medication regimens).

Psychiatrists bring expertise in psychopharmacology, familiarity with stimulants (from treating ADHD), and comfort managing the psychiatric comorbidities common in narcolepsy (depression, anxiety). You already have the DEA registration and clinical skills — you just need to coordinate the sleep study.

PMHNPs (in states with full or reduced practice authority) can provide the same care at lower cost and often better availability. In states like California, New York, and Illinois, you can run a fully independent narcolepsy practice via telehealth. In states like Florida and Texas, you’ll need physician collaboration, but you can still be the primary provider managing day-to-day care.

The regulatory complexity is real, but it’s navigable. And the patient need is enormous.

Next Steps: Getting Started with Telehealth Narcolepsy Care

If you’re a psychiatrist or PMHNP interested in expanding into narcolepsy treatment:

1. Verify your state’s rules — Use the table above and check your state medical/nursing board website for current telehealth and controlled substance prescribing regulations.

2. Get set up for compliance — Enroll in your state’s PDMP, ensure your EPCS platform is DEA-compliant, and if you’re an NP in a restricted state, formalize your collaborative agreement.

3. Build referral relationships — Identify sleep centers in your practice states where you can send patients for diagnostic testing. Many will welcome the referrals.

4. Consider a platform — Instead of spending months and thousands of dollars on SEO and ads, join a provider network like Klarity Health where patients are already searching for specialists like you. You control your schedule, pay only when you see patients, and skip the patient acquisition headache entirely.

5. Stay current — Bookmark the DEA and HHS press pages. When new telemedicine rules are proposed (likely in late 2025 or 2026), read them and comment. These rules will shape your practice.

Narcolepsy patients are underserved, desperate for access, and often willing to pay cash or use insurance for telehealth visits. The regulatory landscape is complex, but the opportunity is clear: psychiatrists and PMHNPs who understand the rules can build thriving, compliant telehealth practices serving a patient population that desperately needs you.

Frequently Asked Questions

Can I prescribe Adderall for narcolepsy via telehealth right now?
Yes, through December 31, 2026, under the DEA’s temporary telehealth flexibilities — as long as you’re licensed in the patient’s state, DEA-registered, and comply with state-specific rules. Exception: Florida prohibits Schedule II prescribing via telehealth for narcolepsy (it’s only allowed for psychiatric disorders). Check your state’s telehealth laws.

What happens when the DEA flexibilities expire?
The DEA will finalize permanent telemedicine rules, likely requiring some form of in-person evaluation or tighter documentation. Providers should plan for hybrid models (partnering with local clinics for initial visits) and stay informed on DEA rulemaking.

Can PMHNPs prescribe stimulants for narcolepsy independently?
It depends on your state. In California, New York, and Illinois, experienced PMHNPs with full practice authority can prescribe Schedule II medications independently. In Texas and Georgia, NPs cannot prescribe Schedule II in outpatient settings at all. In Florida, NPs are limited to 7-day supplies of Schedule II unless treating a psychiatric disorder. Pennsylvania requires physician collaboration and limits initial Schedule II prescriptions to 30 days.

Do I need to see the patient in person for the initial visit?
Under current federal rules (through 2026), no in-person visit is required for telehealth prescribing of controlled substances. However, Florida state law requires an in-person visit to prescribe Schedule II stimulants for narcolepsy (since it’s not a psychiatric disorder). Other states follow federal rules. You will need to coordinate an in-person sleep study (polysomnography and MSLT) to confirm the diagnosis.

What’s the best medication to prescribe via telehealth if I’m worried about regulations?
Modafinil or armodafinil (Schedule IV) are safer bets. They’re effective for many narcolepsy patients, and Schedule IV medications face fewer telehealth restrictions than Schedule II stimulants. Florida, Texas, and other states with Schedule II telehealth bans still allow Schedule IV prescribing remotely.

How do I handle the sleep study requirement in a telehealth-only practice?
You can’t. Narcolepsy diagnosis requires in-person polysomnography and MSLT testing. Build referral relationships with sleep centers in the states where you practice, order the tests remotely, and review the results to confirm diagnosis. For established patients transferring care with documented prior sleep studies, you can continue their medications via telehealth.

Can I use audio-only (phone) visits to prescribe narcolepsy medications?
Generally, no. Most states require video for prescribing controlled substances via telehealth. Texas explicitly mandates two-way audio-visual communication. While some states allowed audio-only during COVID, best practice (and likely future DEA rules) requires video for controlled substance evaluation.

What’s the patient acquisition cost if I market myself independently vs. joining a platform?
DIY marketing (SEO, Google Ads, directories) typically costs $200-500+ per acquired patient when you factor in all costs — and that assumes your campaigns work. SEO takes 6-12 months, Google Ads for mental health keywords cost $15-40+ per click, and directories charge monthly fees plus per-booking fees. Platforms like Klarity use a pay-per-appointment model where you pay a listing fee only when a qualified patient books — no upfront spend, no wasted ad budget.

Do I need special malpractice insurance for telehealth narcolepsy care?
Check with your carrier. Most malpractice policies now cover telehealth, but confirm that controlled substance prescribing via telehealth is included. Some carriers may require additional risk management training or documentation standards.

How often do I need to check the state PDMP?
Nearly all states require checking the prescription drug monitoring program before prescribing controlled substances — typically before the initial prescription and periodically thereafter (every 3-4 months in many states). California requires PDMP checks every 4 months for ongoing Schedule II therapy. Illinois and New York require checks before each controlled prescription. Check your state’s specific requirements.

References

1. U.S. Department of Health and Human Services. ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026.’ Press Release, January 2, 2026. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. U.S. Drug Enforcement Administration. ‘DEA and HHS Extend Telemedicine Flexibilities through 2025.’ Press Release, November 15, 2024. https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025

3. Legal Information Institute, Cornell Law School. ’21 U.S.C. §829(e) – Prescriptions via Internet (Ryan Haight Act).’ U.S. Code, current through 2023. https://www.law.cornell.edu/definitions/uscode.php?def_id=21-USC-1796173870-113781527

4. Nixon Peabody LLP. ‘New York State Finalizes Telemedicine Rule for Controlled Substances.’ Healthcare Alert, June 18, 2025. https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances

5. Florida Legislature. ‘Florida Statute §456.47 – Use of Telehealth to Provide Services.’ 2025 Florida Statutes. https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html

Source:

• https://www.law.cornell.edu/definitions/uscode.php?defid=21-USC-1796173870-113781527&height=800&iframe=true&termoccur=999&term_src=title%3A21%3Achapter%3A13%3Asubchapter%3AI%3Apart%3AC%3Asection%3A831&width=840#:~:text=,that%20a%20prescription%20has%20been
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=promulgate%20a%20final%20set%20of,Medications%2C%E2%80%9D%20was%20submitted%20to%20the
• https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care#:~:text=On%20January%2017%2C%202025%2C%20DEA,to%20as%20the%20%E2%80%9CTwo%20Final
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.tmb.state.tx.us/page/facility-based-prescriptive-delegation#:~:text=at%20the%20hospital%E2%80%99s%20facility,from%20a%20qualified%20hospice%20provider
• https://www.cchpca.org/resources/state-telehealth-laws-and-reimbursement-policies-report-fall-2025/#:~:text=Texas%20regulations%20emphasize%20continuity%20of,Note
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=match%20at%20L114%20The%20rule,and%20the%20US%20Department%20of
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=In%20short%2C%20the%20exception%20permits,as%20a%20condition%20of%20state
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Conversely%2C%20in%20Restricted%20Practice%20states,expand%20this%20scope%20%206